The clinical picture of primary cutaneous diffuse large B-cell... | Download Scientific Diagram
Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma: Trends in Cancer
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study - The Lancet Healthy Longevity
News on Diffuse Large B-Cell Lymphoma » Coping with Cancer
Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma | Annals of Hematology
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study - eClinicalMedicine
Cancers | Free Full-Text | Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study | Indian Journal of Hematology and Blood Transfusion
Treatment resistance in diffuse large B-cell lymphoma | Leukemia
Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma | Immunotherapy
Ibrutinib improves diffuse large B-cell lymphoma survival - NCI
Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma. | Semantic Scholar
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma
Cancers | Free Full-Text | Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
Frontiers | Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B -cell Lymphoma - ScienceDirect
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study | Indian Journal of Hematology and Blood Transfusion
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology
Ibrutinib in B-cell lymphoma: single fighter might be enough? | Cancer Cell International | Full Text
Trial results show that younger lymphoma patients respond well to ibrutinib | Center for Cancer Research
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study - The Lancet Healthy Longevity
JCI Insight - Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations
Frontiers | The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice
